Effects of PC6 acupressure on acute and delayed nausea and vomiting induced by chemotherapy in patients with malignant neoplasm: a meta-analysis.

Abstract

Evaluating the intervention effect of PC6 acupressure on chemotherapy-induced acute, delayed nausea, and vomiting in malignant tumor patients. Eleven databases had been retrieved from January 2010 through January 2022. The published meta-analysis literature was hand-searched, and the language was limited to English and Chinese. The protocol of this meta-analysis was registered with PROSPERO (registration number: CRD42022323693). Two reviewers independently selected relevant eligible articles, extracted data, and evaluated the risk of bias. Meta-analysis was statistically analyzed using software RevMan 5.3. Ten randomized controlled trials with 975 patients were included. Only two studies were assessed as high quality; eight studies were evaluated as moderate. Meta-analysis showed that compared with the control group, PC6 acupressure reduced the occurrence number of acute (SMD = -0.39,95CI (-0.73, -0.05) P= 0.02), delayed (SMD = -0.51, 95% CI (-0.96, -0.05) P= 0.03) nausea and acute (SMD = -0.42,95% CI (-0.79, -0.06) P= 0.02), delayed (SMD = -0.37, 95% CI (-0.77, 0.03) P= 0.07) vomiting; it reduced the severity of acute (SMD = -0.34, 95% CI (-0.57, -0.11) P= 0.004), delayed (SMD = -0.79, 95% CI (-1.33, -0.25) P= 0.004) nausea and acute (SMD = -0.51, 95% CI (-0.79, -0.23) P= 0.0004), delayed (SMD = -0.50, 95% CI (-0.84, -0.17) P= 0.003) vomiting, while it did not reduced the experience time on acute and delayed CINV. The meta-analysis shows the effectiveness of PC6 acupressure in preventing and treating nausea and vomiting. Large, high-quality, well-designed randomized controlled trials are needed in the future to determine the efficacy of PC6 acupressure on chemotherapy-induced nausea and vomiting.